New Stock News | Wohler Bohringer plans to list on the Hong Kong stock market, the China Securities Regulatory Commission requires a supplementary explanation of the reasonableness of the prices at which new shareholders have invested in the past 12 months.

On June 26, the China Securities Regulatory Commission (CSRC) announced the requirements for supplementary materials for overseas issuance and listing filing (June 15, 2026 - June 26, 2026) to be made public. The CSRC International Department issued supplementary material requirements for 8 companies, including Wuhuo Boao needing to explain the reasonableness of the new shareholder investment prices in the past 12 months. It is reported that Wuhuo Boao submitted its listing application to the Hong Kong Stock Exchange on February 27, 2026, with Huatai International as its exclusive sponsor. The CSRC requested the company to provide supplementary explanations for the following matters and asked lawyers to verify and provide clear legal opinions: 1. Please provide supplementary information on the specific compliance status of overseas investments and foreign exchange management procedures of the company's overseas subsidiaries, and provide conclusive opinions on compliance. 2. Please provide supplementary information on whether the company's equity pledge, controlling shareholder and spouse borrowing guarantees, etc., before and after this issuance may lead to major ownership disputes or changes in the company's controlling shareholder, taking into account solvency and other factors. 3. Please provide supplementary explanations on the reasonableness of the new shareholder investment prices in the past 12 months, the reasons for the differences in these investment prices, and provide clear conclusions on the existence of profit transmission, etc. 4. Please provide supplementary explanations on the compliance of the company's implemented equity incentive plan, including the specific composition of personnel, relationships between participants and other shareholders, directors, supervisors, senior management, fairness of prices, agreement conditions, decision-making process, and compliance with regulations, and provide clear conclusions on legality, compliance, and profit transmission. 5. Please provide supplementary explanations on whether the shares held by the shareholders participating in the "full circulation" in this issuance have any pledge, freeze, or other defects. The prospectus shows that Wuhuo Boao is a biopharmaceutical company established in 2010, focusing on the innovation, industrialization, and commercialization of natural drug products with high technological barriers. At the same time, the company has been conducting research on drug delivery systems to overcome the technological bottleneck in drug delivery within the body. As of February 18, 2026, the company has established the following product pipelines: (i) a commercial product, San Bone, for type 2 diabetes; (ii) three core products, including WH007 for polycystic ovary syndrome, WH006 for obesity, and WH002 for neoadjuvant treatment of breast cancer; and (iii) five other candidate drugs.